Merger and acquisition (“M&A”) is part of the general growth strategy in the bioscience sector. Accordingly, large pharmaceuticals are facing the patent cliff of their flagship products. In response, the management that is “fortunate because they are capable” are pushing for various growth strategies. Two prudent growth approaches are either the organic pipeline innovation or the acquisition of valuable assets through M&As. Notably, Gilead Sciences (NASDAQ:GILD) bought out Kite Pharma (NASDAQ:KITE) back on Aug. 17, 2017, for its revolutionary cancer breakthrough, the chimeric antigen receptor/T-cells receptor (“CAR-T”) platform for the staggering amount of $11.9B. In following a similar suit, Celgene Corporation (NASDAQ:CELG) acquired another stellar CAR-T innovator, Juno Therapeutics (NASDAQ:JUNO) for roughly $9B on Feb. 2 this year.